CA3039819A1 - Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders - Google Patents
Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders Download PDFInfo
- Publication number
- CA3039819A1 CA3039819A1 CA3039819A CA3039819A CA3039819A1 CA 3039819 A1 CA3039819 A1 CA 3039819A1 CA 3039819 A CA3039819 A CA 3039819A CA 3039819 A CA3039819 A CA 3039819A CA 3039819 A1 CA3039819 A1 CA 3039819A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- subject
- use according
- day
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407860P | 2016-10-13 | 2016-10-13 | |
| US62/407,860 | 2016-10-13 | ||
| US201662423079P | 2016-11-16 | 2016-11-16 | |
| US62/423,079 | 2016-11-16 | ||
| PCT/US2017/056538 WO2018071784A1 (en) | 2016-10-13 | 2017-10-13 | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3039819A1 true CA3039819A1 (en) | 2018-04-19 |
Family
ID=60191503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3039819A Pending CA3039819A1 (en) | 2016-10-13 | 2017-10-13 | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20190262317A1 (enExample) |
| EP (2) | EP3525784B1 (enExample) |
| JP (4) | JP2019530713A (enExample) |
| KR (4) | KR102528435B1 (enExample) |
| CN (5) | CN114788823A (enExample) |
| AU (3) | AU2017341825B2 (enExample) |
| BR (1) | BR112019007576A2 (enExample) |
| CA (1) | CA3039819A1 (enExample) |
| ES (1) | ES3067967T3 (enExample) |
| MA (1) | MA46524A (enExample) |
| WO (1) | WO2018071784A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7524167B2 (ja) * | 2018-10-04 | 2024-07-29 | トラビア セラピューティクス， インコーポレイテッド | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
| BR112021012226A2 (pt) | 2018-12-21 | 2021-09-08 | Travere Therapeutics, Inc. | Composições de esparsentano amorfo |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| HRP20260121T1 (hr) * | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
| US20230270718A1 (en) * | 2020-04-10 | 2023-08-31 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
| WO2022246200A1 (en) | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
| KR20240051999A (ko) * | 2021-08-26 | 2024-04-22 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도 |
| WO2023127853A1 (ja) * | 2021-12-28 | 2023-07-06 | 株式会社アークメディスン | 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| EP4719402A1 (en) | 2023-05-31 | 2026-04-08 | Travere Therapeutics, Inc. | Sparsentan for use in a method of treating iga-mediated diseases |
| KR20260089488A (ko) | 2023-09-20 | 2026-06-15 | 트래비어 테라퓨틱스, 인코포레이티드 | 면역글로불린 A 신장병증(IgAN)의 치료를 위한 스파르센탄 |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
| WO2026165438A1 (en) | 2025-01-31 | 2026-08-06 | Travere Therapeutics, Inc. | Sparsentan for the treatment of patients post kidney transplantation with proteinuric iga nephropathy or fsgs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID26984A (id) * | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| WO2001044239A2 (en) | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
| WO2010114801A1 (en) * | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| US9719981B2 (en) * | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
| PL3536685T3 (pl) * | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4 |
| JP7524167B2 (ja) | 2018-10-04 | 2024-07-29 | トラビア セラピューティクス， インコーポレイテッド | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
-
2017
- 2017-10-13 JP JP2019519669A patent/JP2019530713A/ja not_active Withdrawn
- 2017-10-13 KR KR1020227032048A patent/KR102528435B1/ko active Active
- 2017-10-13 MA MA046524A patent/MA46524A/fr unknown
- 2017-10-13 EP EP17791821.6A patent/EP3525784B1/en active Active
- 2017-10-13 CA CA3039819A patent/CA3039819A1/en active Pending
- 2017-10-13 CN CN202210441043.8A patent/CN114788823A/zh active Pending
- 2017-10-13 EP EP26154532.1A patent/EP4744733A3/en active Pending
- 2017-10-13 ES ES17791821T patent/ES3067967T3/es active Active
- 2017-10-13 CN CN202311094233.8A patent/CN117017985A/zh active Pending
- 2017-10-13 BR BR112019007576A patent/BR112019007576A2/pt not_active Application Discontinuation
- 2017-10-13 KR KR1020247036666A patent/KR20240162167A/ko active Pending
- 2017-10-13 AU AU2017341825A patent/AU2017341825B2/en active Active
- 2017-10-13 CN CN201780076280.6A patent/CN110049764A/zh active Pending
- 2017-10-13 CN CN202311093985.2A patent/CN117085013A/zh active Pending
- 2017-10-13 KR KR1020237014470A patent/KR20230066644A/ko not_active Ceased
- 2017-10-13 US US16/340,848 patent/US20190262317A1/en not_active Abandoned
- 2017-10-13 CN CN202311092711.1A patent/CN116983302A/zh active Pending
- 2017-10-13 WO PCT/US2017/056538 patent/WO2018071784A1/en not_active Ceased
- 2017-10-13 KR KR1020197011413A patent/KR20190077348A/ko not_active Ceased
-
2020
- 2020-05-22 US US16/882,206 patent/US10864197B2/en active Active
- 2020-11-12 US US17/096,637 patent/US20210196688A1/en not_active Abandoned
-
2022
- 2022-07-15 JP JP2022113881A patent/JP2022137245A/ja active Pending
- 2022-07-15 JP JP2022113880A patent/JP2022141802A/ja active Pending
-
2023
- 2023-08-22 AU AU2023219839A patent/AU2023219839B2/en active Active
-
2024
- 2024-12-20 JP JP2024225044A patent/JP2025060754A/ja active Pending
-
2025
- 2025-06-27 US US19/253,120 patent/US20250325523A1/en active Pending
- 2025-06-27 US US19/253,088 patent/US20250325522A1/en active Pending
- 2025-11-21 AU AU2025271121A patent/AU2025271121A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250325522A1 (en) | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | |
| US20220048900A1 (en) | Amorphous sparsentan compositions | |
| AU2019354784B2 (en) | Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases | |
| WO2022246200A1 (en) | Methods of treating kidney diseases or disorders | |
| WO2024073672A1 (en) | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders | |
| EP4719402A1 (en) | Sparsentan for use in a method of treating iga-mediated diseases | |
| WO2025064688A1 (en) | Sparsentan for treating immunoglobulin a nephropathy (igan) | |
| BR122025008185A2 (pt) | Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo | |
| CA3071096A1 (en) | Co-administration of minocycline and colistin to reduce acute kidney injury | |
| HK40059411A (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| HK40059411B (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220914 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241004 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250911 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251003 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251003 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251030 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251030 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260601 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260601 |